The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, DexCom is now the #9 analyst pick, moving up by 19 spots.
        
This rank is formed by averaging the analyst opinions for each component from each br

S&P 500 Analyst Moves: DXCM

Fintel reports that on October 7, 2026, Barclays initiated coverage of DexCom (NASDAQGS:DXCM) (WBAG:DXCM) with a Overweight recommendation.This initiation follows a prior action by Barclays on May 18, 2026, when the firm maintained an Underweight rating on the stock. DexCom, Inc.

Barclays Initiates Coverage of DexCom with Overweight Rating

(RTTNews) - Dexcom, Inc. (DXCM) released its 2026 State of Type 2 Report, highlighting challenges related to health literacy, technology literacy and systemic access to diabetes technology.

Dexcom Finds CGM Awareness And Access Challenges In Type 2 Diabetes 

DXCM's strong growth, G7 15 Day adoption and CONNECT trial could expand its CGM market opportunity despite reimbursement and competition risks.

Here's Why You Should Retain DexCom Stock in Your Portfolio for Now

The S&P 500 Index ($SPX ) (SPY ) today is closed up +0.23%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.32%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.75%.  September E-mini S&P futures (ESU26 ) are up +0.17%, and September E-mini Nasdaq...

Stock Indexes Supported as Amazon Earnings Bolster Tech Stocks

The S&P 500 Index ($SPX ) (SPY ) today is down -0.02%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.24%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.17%.  September E-mini S&P futures (ESU26 ) are down -0.02%, and September E-mini Nasdaq futures...

Stocks Turn Mixed as Bond Yields Jump

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

DexCom, Inc. News